APACH: PAncreatic Adenocarcinoma in Hospital

Sponsor
Centre Hospitalier Departemental Vendee (Other)
Overall Status
Completed
CT.gov ID
NCT01989624
Collaborator
(none)
1,204
66
85.5
18.2
0.2

Study Details

Study Description

Brief Summary

Few data are currently available in the literature on pancreatic adenocarcinoma in France. About 8,000 new cases each year in France. The 5-year survival for all stages combined is <5%. This is the only digestive cancer in which mortality / incidence ratio is 98%.

Epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (FOLFIRINOX) are mispriced in real life.

The development of new drugs and the development of Phase II and III require a better understanding of the state of this disease in the country.

The main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in France and make an inventory of diagnostic practices and support.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    1204 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    PAncreatic Adenocarcinoma in Hospital
    Actual Study Start Date :
    Oct 18, 2013
    Actual Primary Completion Date :
    Dec 4, 2015
    Actual Study Completion Date :
    Dec 1, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Pancreatic Adenocarcinoma

    Outcome Measures

    Primary Outcome Measures

    1. Survival [patient death (following during 5 year)]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Living in France

    • Pancreatic adenocarcinoma histologically or cytologically proven

    • primary diagnosis

    • Agreed to participate

    Exclusion Criteria:
    • Suspected pancreatic adenocarcinoma histologically or cytologically unproven

    • Refused to participate

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 CH de Jolimont Jolimont Belgium
    2 CH Gabriel Martin Saint-Paul La Réunion France 97866
    3 CHIAP Aix en Provence France 13616
    4 CH Angoulême Angoulême France
    5 CH d'Aubenas Aubenas France 07200
    6 CH Auch Auch France 32008
    7 CH Robert Ballanger Aulnay sous bois France
    8 CH Avignon Avignon France
    9 CH Bagnols sur Ceze Bagnols sur Ceze France
    10 CH Bayeux Bayeux France 14400
    11 CH Blois Blois France 41016
    12 CH Bourg en Bresse Bourg en Bresse France
    13 CH de Bourges Bourges France 18000
    14 CH Nord Deux Sèvres Bressuire France
    15 CH Saint Camille Bry sur Marne France
    16 CH Béziers Béziers France 34500
    17 HPA Castres Mazamet Castres France 81108
    18 CH Chalons en champagne Chalons en champagne France
    19 CH Chambery Chambery France
    20 CH Chartres Chartres France 28630
    21 Ch Cholet Cholet France
    22 CH Haut Anjou Château Gontier France
    23 CH Châteauroux Châteauroux France 36000
    24 CH Compiègne Noyon Compiègne France
    25 CH sud francilien Corbeil Essonnes France
    26 CH de Creil Creil France 60109
    27 CHI Créteil Créteil France 94000
    28 CH Dourdan Dourdan France
    29 CH Draguignan Draguignan France
    30 CH Dreux Dreux France 28100
    31 CH Simone Veil Eaubonne France 95600
    32 CH Forcilles Ferolles France
    33 Chicas Gap France
    34 CH Gonesse Gonesse France 95500
    35 Centre hospitalier départemental Vendée La Roche sur Yon France 85925
    36 Centre Hospitalier de Lagny Lagny sur Marne France 77400
    37 CH du Mans Le Mans France
    38 Lens Lens France
    39 Centre Hospitalier Côté de lumière Les Sables d'Olonne France 85100
    40 Hôpital des chanaux Macon France
    41 Centre Hospitalier de Meaux Meaux France 77100
    42 CH Melun Melun France
    43 CHR de Mercy-Metz Metz France
    44 CHAM Montargis France 45207
    45 CH Montauban Montauban France
    46 Centre Hospitalier Montelimar Montelimar France 26200
    47 CH Montfermeil Montfermeil France
    48 CH Niort Niort France
    49 CHG Oloron Oloron Sainte Marie France
    50 CHR Orléans Orléans France 45000
    51 CH François Mitterand Pau France
    52 Centre Hospitalier de Perpignan Perpignan France 66046
    53 CHI Poissy Saint Germain Poissy France 78600
    54 CH Pontoise Pontoise France
    55 CH de la région d'Annecy Pringy France 74374
    56 CH Quimper Quimper France 29107
    57 CH Roubaix Roubaix France
    58 Centre hospitalier Yves Le Foll Saint Brieuc France 22200
    59 CH Saint Quentin Saint Quentin France
    60 CH de la Fontaine Saint-Denis France
    61 Centre Hospitalier de Bigorre Tarbes France 65013
    62 CH Sainte Musse Toulon France
    63 CH Tourcoing Tourcoing France
    64 CH Valenciennes Valenciennes France
    65 CHBA de Vannes Vannes France 56017
    66 CHIV Villeneuve Saint-Georges Villeneuve Saint-Georges France 94190

    Sponsors and Collaborators

    • Centre Hospitalier Departemental Vendee

    Investigators

    • Principal Investigator: Roger FAROUX, PH, Centre hospitalier départemental Vendée

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Centre Hospitalier Departemental Vendee
    ClinicalTrials.gov Identifier:
    NCT01989624
    Other Study ID Numbers:
    • CHD064-13
    First Posted:
    Nov 21, 2013
    Last Update Posted:
    Mar 14, 2022
    Last Verified:
    Mar 1, 2022
    Keywords provided by Centre Hospitalier Departemental Vendee
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 14, 2022